Lead: S. Thai Thayumanavan
Amount: $100000
Intellectual Property Status: Patent
Award Date: 09/24/2024
ABSTRACT
Nalam Therapeutics is developing a platform for universal inclusion of chemotherapeutic drugs in ADC-like formats, overcoming current limitations of drug-to-antibody ratios and linker restrictions. The platform aims to disruptively impact the $9.7B ADC market. Nalam’s goal is to enhance the safety and efficacy profiles of these drugs, improving patient outcomes.
This is not the NSF website for the ART program. The development of this portal is supported by the U.S. National Science Foundation under Award No. 2331429. The material on this portal is sourced from the various activities and projects being supported the ART program. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the U.S. National Science Foundation.
